title: Antibodies Directed against Shiga-Toxin Producing Escherichia coli Serotype O103 Type III Secreted Proteins Block Adherence of Heterologous STEC Serotypes to HEp-2 Cells.
abstract: Shiga toxin-producing Escherichia coli (STEC) serotype O103 is a zoonotic pathogen that is capable of causing hemorrhagic colitis and hemolytic uremic syndrome (HUS) in humans. The main animal reservoir for STEC is ruminants and hence reducing the levels of this pathogen in cattle could ultimately lower the risk of STEC infection in humans. During the process of infection, STECO103 uses a Type III Secretion System (T3SS) to secrete effector proteins (T3SPs) that result in the formation of attaching and effacing (A/E) lesions. Vaccination of cattle with STEC serotype O157 T3SPs has previously been shown to be effective in reducing shedding of STECO157 in a serotype-specific manner. In this study, we tested the ability of rabbit polyclonal sera against individual STECO103 T3SPs to block adherence of the organism to HEp-2 cells. Our results demonstrate that pooled sera against EspA, EspB, EspF, NleA and Tir significantly lowered the adherence of STECO103 relative to pre-immune sera. Likewise, pooled anti-STECO103 sera were also able to block adherence by STECO157. Vaccination of mice with STECO103 recombinant proteins induced strong IgG antibody responses against EspA, EspB, NleA and Tir but not against EspF. However, the vaccine did not affect fecal shedding of STECO103 compared to the PBS vaccinated group over the duration of the experiment. Cross reactivity studies using sera against STECO103 recombinant proteins revealed a high degree of cross reactivity with STECO26 and STECO111 proteins implying that sera against STECO103 proteins could potentially provide neutralization of attachment to epithelial cells by heterologous STEC serotypes.
authors.affiliation: Vaccine & Infectious Disease Organization-International Vaccine Center, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
authors.forename: Taseen S
authors.initials: TS
authors.lastname: Desin
authors.affiliation: Vaccine & Infectious Disease Organization-International Vaccine Center, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
authors.forename: Hugh G
authors.initials: HG
authors.lastname: Townsend
authors.affiliation: Vaccine & Infectious Disease Organization-International Vaccine Center, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
authors.forename: Andrew A
authors.initials: AA
authors.lastname: Potter
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology / Q000494:pharmacology*; D001422:Bacterial Adhesion / Q000276:immunology; D058947:Bacterial Secretion Systems / Q000276:immunology*; D002417:Cattle; D002460:Cell Line; D003429:Cross Reactions; D054324:Enterohemorrhagic Escherichia coli / Q000276:immunology* / Q000472:pathogenicity; D029968:Escherichia coli Proteins / Q000276:immunology*; D022361:Escherichia coli Vaccines / Q000276:immunology / Q000494:pharmacology; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D051379:Mice; D011817:Rabbits
chemical_list: D000907:Antibodies, Bacterial; D058947:Bacterial Secretion Systems; D029968:Escherichia coli Proteins; D022361:Escherichia coli Vaccines; D007074:Immunoglobulin G